PL434495A1 - Zastosowanie wanikozydów - Google Patents
Zastosowanie wanikozydówInfo
- Publication number
- PL434495A1 PL434495A1 PL434495A PL43449520A PL434495A1 PL 434495 A1 PL434495 A1 PL 434495A1 PL 434495 A PL434495 A PL 434495A PL 43449520 A PL43449520 A PL 43449520A PL 434495 A1 PL434495 A1 PL 434495A1
- Authority
- PL
- Poland
- Prior art keywords
- vanicoside
- vanicosides
- sakhalin
- phenylpropanoid
- knotweed
- Prior art date
Links
- 229930187097 vanicoside Natural products 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- RNXDQKHOEWIRNH-UHFFFAOYSA-N Vanicoside A Natural products C1=C(O)C(OC)=CC(C=CC(=O)OCC2C(C(O)C(OC(C)=O)C(OC3(COC(=O)C=CC=4C=CC(O)=CC=4)C(C(O)C(COC(=O)C=CC=4C=CC(O)=CC=4)O3)OC(=O)C=CC=3C=CC(O)=CC=3)O2)O)=C1 RNXDQKHOEWIRNH-UHFFFAOYSA-N 0.000 abstract 1
- RNXDQKHOEWIRNH-FBMBONOOSA-N [(2r,3r,4s,5r)-5-[(2r,3r,4s,5s,6r)-3-acetyloxy-4,5-dihydroxy-6-[[(e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxymethyl]oxan-2-yl]oxy-3-hydroxy-4-[(e)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy-5-[[(e)-3-(4-hydroxyphenyl)prop-2-enoyl]oxymethyl]oxolan-2-yl]methy Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)OC[C@@H]2[C@H]([C@H](O)[C@@H](OC(C)=O)[C@@H](O[C@]3(COC(=O)\C=C\C=4C=CC(O)=CC=4)[C@H]([C@H](O)[C@@H](COC(=O)\C=C\C=4C=CC(O)=CC=4)O3)OC(=O)\C=C\C=3C=CC(O)=CC=3)O2)O)=C1 RNXDQKHOEWIRNH-FBMBONOOSA-N 0.000 abstract 1
- ALSDWGAQQGXOHC-PWYSLETCSA-N [(2r,3r,4s,5s)-3-hydroxy-4-[(e)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy-5-[[(e)-3-(4-hydroxyphenyl)prop-2-enoyl]oxymethyl]-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxymethyl]oxan-2-yl]oxyoxolan-2-yl]methyl (e)-3-( Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@]3(COC(=O)\C=C\C=4C=CC(O)=CC=4)[C@H]([C@H](O)[C@@H](COC(=O)\C=C\C=4C=CC(O)=CC=4)O3)OC(=O)\C=C\C=3C=CC(O)=CC=3)O2)O)=C1 ALSDWGAQQGXOHC-PWYSLETCSA-N 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 229930015704 phenylpropanoid Natural products 0.000 abstract 1
- -1 phenylpropanoid disaccharide esters Chemical class 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- ALSDWGAQQGXOHC-KHKJGWCUSA-N vanicoside B Natural products O=C(OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(COC(=O)/C=C/c3ccc(O)cc3)[C@@H](OC(=O)/C=C/c3ccc(O)cc3)[C@H](O)[C@@H](COC(=O)/C=C/c3ccc(O)cc3)O2)O1)/C=C/c1cc(OC)c(O)cc1 ALSDWGAQQGXOHC-KHKJGWCUSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Zgłoszenie dotyczy aktywności przeciwnowotworowych disacharydowych estrów fenylopropanoidów izolowanych z kłączy rdestowca sachalińskiego. Związki te znane są jako wanikozyd A i wanikozyd B i zgodnie z wynalazkiem nadają się do stosowania w leczeniu lub profilaktyce nowotworów, zwłaszcza czerniaka.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL434495A PL243663B1 (pl) | 2020-06-29 | 2020-06-29 | Zastosowanie wanikozydów |
| PCT/PL2021/050049 WO2022005316A1 (en) | 2020-06-29 | 2021-06-29 | Use of vanicosides |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL434495A PL243663B1 (pl) | 2020-06-29 | 2020-06-29 | Zastosowanie wanikozydów |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL434495A1 true PL434495A1 (pl) | 2022-01-03 |
| PL243663B1 PL243663B1 (pl) | 2023-09-25 |
Family
ID=77802213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL434495A PL243663B1 (pl) | 2020-06-29 | 2020-06-29 | Zastosowanie wanikozydów |
Country Status (2)
| Country | Link |
|---|---|
| PL (1) | PL243663B1 (pl) |
| WO (1) | WO2022005316A1 (pl) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3589B1 (ar) * | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| US20180185302A1 (en) * | 2015-06-30 | 2018-07-05 | Regents Of The University Of Minnesota | Methods for downregulating apobec3b |
-
2020
- 2020-06-29 PL PL434495A patent/PL243663B1/pl unknown
-
2021
- 2021-06-29 WO PCT/PL2021/050049 patent/WO2022005316A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PL243663B1 (pl) | 2023-09-25 |
| WO2022005316A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120361T1 (el) | Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido) | |
| ZA202003176B (en) | Compounds useful as kinase inhibitors | |
| WO2020160193A3 (en) | Compounds and uses thereof | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| EA033395B1 (ru) | Ингибиторы индоламин-2,3-диоксигеназы и способы их применения | |
| MX2015017486A (es) | Inhibidores de indolamina 2,3-dioxigenasa (dio). | |
| UY37870A (es) | Inhibidores de kras g12c y métodos para utilizarlos campo de la invención | |
| BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
| EP3679063A4 (en) | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER | |
| UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
| PH12015502028A1 (en) | Ido inhibitors | |
| SA519410320B1 (ar) | مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل | |
| MX366875B (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
| EA201890858A1 (ru) | 2,4-дигидроксиникотинамиды как агонисты apj | |
| MY189454A (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| WO2019023315A3 (en) | Rac inhibitors | |
| MX2017015923A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). | |
| CO2022000214A2 (es) | Composiciones para el tratamiento de la pérdida del cabello | |
| PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
| MX381092B (es) | Inhibidores de fucosidasa. | |
| CO2024001405A2 (es) | Composiciones y métodos para el tratamiento de cáncer | |
| NZ746011A (en) | Glycoalkaloid combinations and various uses thereof | |
| PH12021552389A1 (en) | Quinoline derivatives and their use for the treatment of cancer | |
| MX2021009195A (es) | Metodos y composiciones para el tratamiento del cancer. | |
| MY208133A (en) | Bicyclic heteroaryl derivatives |